Management of frontline ALK+ NSCLC: brigatinib vs. alectinib

Following the release of data from the ALTA-1 trial, the management of frontline ALK+ non-small cell lung cancer (NSCLC) is changing. Riyaz Shah, FRCP, PhD, The Royal Marsden Hospital, London, UK, highlights how where crizotinib was once the standard of care, brigatinib and alectinib are emerging. He emphasizes the need for a head-to-head trial comparing brigatinib and alectinib. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.